Long-term effects of antilipidaemic therapy on left ventricular function in patients with dyslipidaemia: multigated radionuclide ventriculography study

Nuclear Medicine Communications

Volumn 26, Issue 9, 2005, Pages 773-779

  Entok, Emre ^a   Ünalir, Ahmet ^a   Cavusoglu, Yuksel ^a   Timuralp, Bilgin ^a   Vardareli, Erkan ^a  

^a Osmangazi University Hospital   (Turkey)

Author keywords

Dyslipidaemia; Radionuclide ventriculography; Therapy

Indexed keywords

ANTILIPEMIC AGENT; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; EXERCISE TEST; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MALE; RADIOISOTOPE VENTRICULOGRAPHY; TREADMILL EXERCISE; VALVULAR HEART DISEASE;

ANTILIPEMIC AGENTS; DYSLIPIDEMIAS; FATTY ACIDS, MONOUNSATURATED; FEMALE; GATED BLOOD-POOL IMAGING; HUMANS; INDOLES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 24044458569     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000172740.98369.ed     Document Type: Article

References (82)

1. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999; 340:115-126.
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104:365-372.
3. Zeiher AM, Drexier H, Wolischiager H, Just H. Modulation of coronary vasomotor tone: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83:391-401.
4. Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon 3rd RO. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995; 92:320-326.
5. Schachinger V, Zeiher AM. Quantitative assessment of coronary vasoreactivity in humans in-vivo.Circulation 1995; 92:2087-2094.
6. Kuo L, Davis MJ, Chilian WM. Longitudinal gradients for endothelium-dependent and independent vascular responses in the coronary microcirculation. Circulation 1995; 92:518-525.
7. Uren NG, Marraccini P, Gistri R, Desilva R, Camici PG. Altered coronary vasodilator reserve and metabolism in myocardium subtended by normal arteries in patients with coronary artery disease. J Am Coll Cardiol 1993; 22:650-658.
8. Reddy KG, Nair RV, Sheehan HM, Hodgson JM. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994; 23:833-843.
9. Harrison DG. Endothelial dysfunction in the coronary microcirculation: a new clinical entity or an experimental finding? J Clin Invest 1993; 91:1-2.
10. Chilian WM, Dellsperger KC, Layne SM, Eastham CL, Armstrong MA, Marcus ML, Heistad DD. Effects of atherosclerosis on the coronary microcirculation. Am J Physiol 1990; 258(2, pt 2):H529-H539.
11. Selke FW, Armstrong ML, Harrison DG. Endothelium dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation 1990; 81:1586-1593.
12. Zeiher AM, Drexier H, Wolischiager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84:1984-1992.
13. Tomita T, Ezaki M, Miwa M, Nakamura K, lnoue Y. Rapid and reversible inhibition by low density lipoprotein of the endothelium-dependent relaxation to hemostatic substances in porcine coronary arteries. Circ Res 1990; 66:18-27.
14. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. lnvestigation of decreased availability of nitric oxide precursor as the mechanism responsible for impaired endothelium-dependent vasodilation in hypercholesterolemic patients. J Am Coll Cardiol 1994; 23:844-850.
15. Benzuly KH, Padgett RC, Kaul S, Piegors DJ, Armstrong ML, Heistad DD. Functional improvement precedes structural regression of atherosclerosis. Circulation 1994; 89:1810-1818.
16. Frank MW, Harris KR, Ahlin KA, Klocke FJ. Endothelium derived relaxing factor (nitric oxide) has a tonic vasodilating action on coronary collateral vessels. J Am Coll Cardiol 1996; 27:658-663.
17. Lundman P, Eriksson M, Schenck-Gustafsson K, Karpe F, Tornvali P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation 1997; 96:3266-3268.
18. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89:1329-1445.
19. Stone NJ, Nicolosi RJ, Kris-Etherton P, Ernst ND, Krauss RM, Winston M. AHA conference proceedings. Summary of the scientific conference on the efficacy of hypocholesterolemic dietary interventions. American Heart Association. Circulation 1996; 94:3388-3391.
20. Ballantyne CM, Herd JA, Stein EA, Ferlic LL, Dunn JK, Gotto AM Jr, Marian AJ. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 2000; 36:1572-1578.
21. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89:2519-2524.
22. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481-487.
23. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, Dudrick SJ. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994; 89:1530-1538.
24. Eichstadt HW, Eskotter H, Hoffman I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76:122A-125A.
25. Jones RH, McEwan P, Newman GE, Port S, Rerych SK, Scholz PM, et al. Accuracy of diagnosis of coronary artery disease by radionuclide management of left ventricular function during rest and exercise. Circulation 1981; 64:586-601.
26. Jones RH, Floyd RD, Austin EH, Sabiston Jr DC. The role of radionuclide angiocardiography in the preoperative prediction of pain relief and prolonged survival following coronary artery bypass grafting. Ann Surg 1983; 197:743-754.
27. Bonow RO, Kent KM, Rosing DR, Lan KK, Lakatos E, Borer JS, et al. Exercise-induced ischemia in mildly symptomatic patients with coronary-artery disease and preserved left ventricular function. Identification of subgroups at risk of death during medical therapy. N Engl J Med 1984; 311:1339-1345.
28. Bonow RO, Vitale DF, Bacharach SL, Frederick TM, Kent KM, Green MV. Asynchronous left ventricular regional function and impaired global diastolic filling in patients with coronary artery disease: reversal after coronary angioplasty. Circulation 1985; 71:297-307.
29. Wackers FJ, Berger HJ, Johnstone DG. Multiple gated cardiac blood pool imaging for left ventricular ejection fraction: validation of the technique and assessment of variability. Am J Cardiol 1979; 43:1159-1165.
30. Hecht HS, Josephson MA, Hopkins JM, Singh BN, Parzen E, Elasroff J. Reproducibility of equilibrium radionuclide ventriculography in patients with coronary artery disease: response of left ventricular ejection fraction and regional wall motion to supine bicycle exercise. Am Heart J 1982; 104:567-574.
31. Magorien DJ, Shaffer P, Bush C, Magorien RD, Kolibash AJ, Unverferth DV, Bashore TM. Hemodynamic correlates for timing intervals, ejection rate and filling rate derived from the radionuclide angiographic volume curve. Am J Cardiol 1984; 53:567-571.
32. Mancini GBJ, Slutsky RA, Norris SL, Bhargava V, Ashburn WL, Higgins CB. Radionuclide analysis of peak filling rate, filling fraction, and time to peak filling rate. Reponse to supine bicycle exercise in normal subjects and patients with coronary disease. Am J Cardiol 1983; 51:43-51.
33. Slutsky RA, Mancini GBJ, Gerber K, Carey K, Ashburn WL, Higgins CB. Radionuclide analysis of ejection time, peak ejection rate, and time to peak ejection rate. Response to supine bicycle exercise in normal subjects and patients with coronary heart disease. Am Heart J 1983; 105:802-810.
34. Bronzwaer JG, de Bruyne B, Ascoop CA, Paulus WJ. Comparative effects of pacing-induced and balloon coronary occlusion ischemia on left ventricular diastolic function in man. Circulation 1991; 84:211-222.
35. Carroll JD, Hess OM, Hirzel HO, Turina M, Krayenbuehl HP. Effects of ischemia, bypass surgery and past infarction on myocardial contraction, relaxation and compliance during exercise. Am J Cardiol 1989; 63:65e-71e.
36. Glynn RB, Narveson LG, Hung JC, Gibbons RJ. Adjustment to radionuclide angiograms dosa based upon patients' physical parameters. J Nucl Med Tech 1994; 22:17-20.
37. Udelson JE, Bonow RO. Radionuclide angiographic evaluation of left ventricular diastolic function. In: Gaasch WH, LeWinter MM (editors): Left Ventricular Diastolic Dysfunction and Heart Failure. Philadelphia: Lea & Febiger; 1994, pp. 167-191.
38. Dougherty AH, Maccarilli GV, Gray EL, Hicks CH, Goldstein RA. Congestive heart failure with normal systolic function. Am J Cardiol 1984; 54:778-782.
39. Soufer R, Wohlgelenter D, Vita NA, Amuchestegui M, Sostman HD, Berger HJ, et al. Intact systolic left ventricular function in clinical congestive heart failure. Am J Cardiol 1985; 55:1032-1036.
40. Mandinov L, Eberli FR, Seiler C, Hess OM. Diastolic heart failure. Cardiovas Res 2000; 45:813-825.
41. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II causal mechanisms and treatment. Circulation 2002; 105:1503-1508.
42. Apstein CS, Morgan JP. Cellular mechanisms underlying left ventricular diastolic dysfunction. In: Gaasch WH, LeWinter MM (editors): Left Ventricular Diastolic Dysfunction and Heart Failure. Philadelphia: Lea & Febiger; 1994, pp. 3-24.
43. Huang Y, Walker KE, Hanley F, Narula J, Houser SR, Tulenko TN. Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. Circulation 2004; 109:97-102.
44. Salmasi AM, Frost P, Dancy M. Impaired left ventricular diastolic function during isometric exercise in asymptomatic patients with hyperlipidaemia. Int J Cardiol 2004; 95:275-280.
45. Perrone-Filardi P, Bacharach SL, Dilsizian V, Bonow RO. Effects of regional systolic asynchrony on left ventricular global diastolic function in patients with coronary artery disease. J Am Coll Cardiol 1992; 19:739-744.
46. Vanoverschelde JL, Wijn W, Michel X, Cosyns J, Detry JM. Asynchronous (segmental early) relaxation impairs left ventricular filling in patients with coronary artery disease and normal systolic function. J Am Coll Cardiol 1991; 18:1251-1258.
47. Ludbrook PA, Byrne JB, Tiefenbrunn AJ. Association of asynchronous protodiastolic segmental wall motion with impaired left ventricular relaxation. Circulation 1981; 64:1201-1211.
48. Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathophysiology and therapeutic implications. J Am Coll Cardiol 1993; 22:318-325.
49. Huang Y, Walker KE, Hanley F, Narula J, Houser SR, Tulenko TN. Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. Circulation 2004; 109:97-102.
50. Wang T, Lee C, Wu C, Lee TM, Chen WJ, Chen MF, et al. The effects of dyslipidemia on left ventricular systolic function in patients with stable angina pectoris. Atherosclerosis 1999; 146:117-124.
51. Motz W, Wogt M, Rabenan O, Scheler S, Luckhoff A, Strauer BE. Evidence of endothelial dysfunction in coronary resistance vessels in patients with angina pectoris and normal coronary angiograms. Am J Cardiol 1991; 68:996-1003.
52. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 1993; 328:1659-1664.
53. Hessler JR, Robertson Jr AL, Chisolm III GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979; 32:213-219.
54. Matsuda Y, Hirata K, Inoue N, Suematsu M, Kawashima S, Akita H, Yokoyama M. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res 1993; 72:1103-1109.
55. Stimpel M, Neyses L, Locher R, Knorr M, Vetter W. High-density lipoprotein-modulators of the calcium channel? J Hyperten 1986; 3(suppl 3):49-51.
56. Mintz GS, Painter JA, Pichard AD, Kent KM, Satler LF, Popma JJ, et al. Atherosclerosis in angiographically normal coronary artery reference segments: an intravascular ultrasound study with clinical correlations. J Am Coll Cardiol 1995; 25:1479-1485.
57. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95:1126-1131.
58. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279:1643-1650.
59. Bastiaanse EM, Atsma DE, Kuijpers MM, Van der Laarse A. The effect of sarcolemmal cholesterol content on intracellular calcium ion concentration in cultured cardiomyocytes. Arch Biochem Biophys 1994; 313:58-63.
60. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Med 2000; 6:1004-1010.
61. Strehlow K, Wassmann S, Bohm M, Nickenig G. Angiotensin AT receptor over-expression in hypercholesterolaemia. Ann Med 2000; 32:386-389.
62. Pliquett RU, Cornish KG, Zucker IH. Statins: the effects on sympathetic nerve activity in heart failure [Abstract]. J Card Fail 2001; 7(suppl l2):16A.
63. Rosnenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353:983-984.
64. Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur J Pharmacol 2000; 410:83-92.
65. Luo JD, Zhang WW, Zhang GP, Guan JX, Chen X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 1999; 26:903-908.
66. Oi S, Haneda T, Osaki J, Kashiwagi Y, Nakamura Y, Kawabe J, Kikuchi K. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 1999; 376:139-148.
67. Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, Cannon 3rd RO. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994; 90:35-41.
68. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89:2519-2524.
69. Vallance P, Collier J, Moncada S. Effects of endothelium derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2:997-1000.
70. Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy human. J Hypertens 1993; 11:1375-1380.
71. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase.J Biol Chem 1995; 270:319-324.
72. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized LDL. J Clin Invest 1992; 339:883-887.
73. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101:2711-2719.
74. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97:1129-1135.
75. Zeiher AM, Drexler H, Wollschläger H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84:1984-1992.
76. Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire M, Schwaiger M. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation 1994; 90:808-817.
77. Yokoyama I, Ohtake T, Momomura S, Nishikawa J, Sasaki Y, Omata M. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation 1996; 94:3232-3238.
78. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89:2519-2524.
79. Anderson TA, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium dependent coronary vasomotion. N Engl J Med 1995; 332:488-493.
80. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481-487.
81. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, Dudrick SJ. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing endothelium. Circulation 1994; 89:1530-1538.
82. Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999; 99:2871-2875.